摘要
目的探讨紫杉醇脂质体联合贝伐珠单抗治疗中晚期胃癌的疗效及其对免疫功能的影响。方法选取90例中晚期胃癌患者，采取随机数字表法分为对照组与观察组，每组45例。对照组给予紫杉醇脂质体联合卡培他滨方案化疗，观察组在对照组的基础上加用贝伐珠单抗治疗。比较两组临床疗效、不良反应发生率、生活质量（QL-index指数量表）评分及免疫功能变化。结果观察组总有效率为64.44%，明显高于对照组的51.11%，差异有统计学意义（χ2＝7.67，P〈0.05）。两组治疗后与治疗前相比生活质量评分均提高（均P〈0.05），且观察组升高更加显著（t＝5.89，P〈0.05）。两组治疗后与治疗前相比CD3＋、CD4＋、CD8＋水平均降低（均P〈0.05），对照组治疗后与观察组治疗后相比上述指标降低更加显著（t＝3.35、4.25、3.78，均P〈0.05）。结论紫杉醇脂质体联合贝伐珠单抗治疗中晚期胃癌的疗效突出，安全性较高，能够促进提高患者的生活质量，改善免疫功能。
ObjectiveTo explore the effect of paclitaxel liposomes scheme combined with bevacizumab in the treatment of advanced gastric cancer and its effect on immune function.MethodsA total of 90 patients with middle-late gastric cancer were selected, and they were randomly divided into control group and observation group according to the digital table, with 45 cases in each group.The control group was given paclitaxel liposome combined with capecitabine chemotherapy, and the observation group was treated with beacizumab on the basis of the control group.The clinical curative effect, incidence rate of adverse reaction, quality of life（QL-index） score and immune function change were compared between the two groups.ResultsThe total effective rate of the observation group was 64.44%, which was significantly higher than 51.11% of the control group （χ2=7.67, P〈0.05）. Compared with before treatment, the quality of life scores in the two groups after treatment were improved（all P〈0.05）, which in the observation group were improved more significantly compared with the control group（t=5.89, P〈0.05）. Compared with before treatment, the CD3＋ , CD4＋ , CD8＋ levels in the two groups after treatment were reduced（all P〈0.05）, which in the observation group were reduced more significantly compared with the control group（t=3.35, 4.25, 3.78, all P〈0.05）.ConclusionThe paclitaxel liposomes scheme combined with bevacizumab in the treatment of advanced gastric cancer is prominent and safe, which can promote the quality of life of patients and improve the immune function.
作者
葛琳
Ge Lin.(Department of Pharmacy, the People ＇s Hospital of Zhejiang Province （ the People ＂s Hospital Affiliated to Hangzhou Medical College ）, Hangzhou, Zhejiang 3 10000, China)
出处
《中国基层医药》
CAS
2018年第11期1387-1390,共4页
Chinese Journal of Primary Medicine and Pharmacy
基金
浙江省自然科学基金项目（Y16H310016）
关键词
胃肿瘤
紫杉醇脂质体
贝伐珠单抗
免疫
细胞
Stomach neoplasms
Paclitaxel liposomes
Bevacizumab
Immunity
cellular
